


Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
by Christina Black | May 9, 2018
...
PD-L1 driven excluded phenotype in melanoma
by Christina Black | Apr 14, 2018

Comprehensive Immune and Mutational Profile of Melanoma
by OmniSeq Staff | Jan 25, 2018

CTLA-4 Overexpression Does Not Confer Response to Ipilimumab in Melanoma
by OmniSeq Staff | Jan 13, 2018
Follow Us on Twitter
LABCORP EXPANDS ACCESS TO COMPREHENSIVE GENOMIC TESTING THROUGH NEW LUNG CANCER PROGRAM UTILIZING OmniSeq INSIGHT
https://tinyurl.com/59xf82c6
@OmniSeq
@Labcorp
#oncology
#precisionmedicine
Last year, the Buffalo-based cancer diagnostics firm @OmniSeq quietly was acquired by one of the world's largest life science companies, @Labcorp . Developing molecular diagnostic tests for cancer patients, OmniSeq is looking to scale its operations.
https://tinyurl.com/muxryphz